Treatment of skin disorders with compositions comprising an EGFR inhibitor
This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.
1. A method of treatment or alleviation of psoriasis by topical administration to a subject in need thereof of a composition comprising a therapeutically effective amount of erlotinib, or a pharmaceutically acceptable salt thereof, in a concentration of from about 3% to about 5% w/w or from about 5% to about 10% w/w.
2. A method of treatment or alleviation of psoriasis by topical administration to a subject in need thereof of a composition comprising:
(i) a therapeutically effective amount of erlotinib, or a pharmaceutically acceptable salt thereof, in a concentration of from about 3% to about 5% w/w or from about 5% to about 10% w/w; and
(ii) at least one additional active agent selected from the first active agent group consisting of a corticosteroid, calcipotriene, tapinarof, a Janus kinase inhibitor (JAK inhibitor), a phosphodiesterase-4 inhibitor (PDE4 inhibitor), and combinations thereof, in a concentration of from about 0.01% to about 1%, from about 1% to about 3%, or from about 3% to about 5% w/w.
3. The method of claim 2 , wherein the method further comprises administering a composition comprising at least one additional active agent selected from the second active agent group consisting of menadione, ketoconazole, dapsone, cevimeline, spironolactone, tretinoin, pimecrolimus, a tetracycline, a sunscreen, doxycycline, epidermal growth factor (EGF), lycopene, threolone, synthomycine, erythromycin, Vitamin K3 and combinations thereof, in a concentration of from about 0.01% to about 1%, from about 1% to about 3%, or from about 3% to about 5% w/w, wherein the two separate compositions are administered concomitantly or sequentially, in either order.
4. A method of treatment or alleviation of psoriasis by topical administration to a subject in need thereof of a composition comprising:
(i) a therapeutically effective amount of erlotinib, or a pharmaceutically acceptable salt thereof, in a concentration of from about 3% to about 5% w/w or from about 5% to about 10% w/w; and
(ii) at least one additional active agent selected from the second active agent group consisting of menadione, ketoconazole, dapsone, cevimeline, spironolactone, tretinoin, pimecrolimus, a tetracycline, a sunscreen, doxycycline, epidermal growth factor (EGF), lycopene, threolone, synthomycine, erythromycin, Vitamin K3 and combinations thereof, in a concentration of from about 0.01% to about 1%, from about 1% to about 3%, from about 3% to about 5% w/w.
5. The method of claim 4 , wherein the method further comprises administering a composition comprising at least one additional active agent selected from the first active agent group consisting of a corticosteroid, calcipotriene, tapinarof, a Janus kinase inhibitor (JAK inhibitor), a phosphodiesterase-4 inhibitor (PDE4 inhibitor), and combinations thereof, in a concentration of from about 0.01% to about 1%, from about 1% to about 3%, or from about 3% to about 5% w/w.
6. A method of treatment or alleviation of psoriasis by topical administration to a subject in need thereof of a composition comprising:
(i) a therapeutically effective amount of erlotinib, or a pharmaceutically acceptable salt thereof, in a concentration of from about 3% to about 5% w/w or from about 5% to about 10% w/w;
(ii) at least one additional active agent selected from the first active agent group consisting of a corticosteroid, calcipotriene, tapinarof, a Janus kinase inhibitor (JAK inhibitor), a phosphodiesterase-4 inhibitor (PDE4 inhibitor), and combinations thereof, in a concentration of from about 0.01% to about 1%, from about 1% to about 3%, or from about 3% to about 5% w/w; and
(iii) at least one additional active agent selected from the second active agent group consisting of menadione, ketoconazole, dapsone, cevimeline, spironolactone, tretinoin, pimecrolimus, a tetracycline, a sunscreen, doxycycline, epidermal growth factor (EGF), lycopene, threolone, synthomycine, erythromycin, Vitamin K3 and combinations thereof, in a concentration of from about 0.01% to about 1%, from about 1% to about 3%, or from about 3% to about 5% w/w.
7. The method of claim 1 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride and from about 10% to about 98% w/w at least one penetration enhancer.
8. The method of 2 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride and from about 10% to about 98% w/w at least one penetration enhancer.
9. The method of 4 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride and from about 10% to about 98% w/w at least one penetration enhancer.
10. The method of 6 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride and from about 10% to about 98% w/w at least one penetration enhancer.
11. The method of claim 1 , wherein the method does not induce or induces reduced cutaneous side-effects as compared with systemic administration of the same amount of erlotinib, or of the pharmaceutically acceptable salt thereof.
12. The method of claim 2 , wherein the method does not induce or induces reduced cutaneous side-effects as compared with systemic administration of the same amount of erlotinib, or the pharmaceutically acceptable salt thereof.
13. The method of claim 4 , wherein the method does not induce or induces reduced cutaneous side-effects as compared with systemic administration of the same amount of erlotinib, or the pharmaceutically acceptable salt thereof.
14. The method of claim 6 , wherein the method does not induce or induces reduced cutaneous side-effects as compared with systemic administration of the same amount of erlotinib, or the pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein the method comprises once or twice daily topical application of therapeutically effective amounts of the said composition to the skin portion of the subject affected by said psoriasis until the skin is cured or alleviated or according to doctor's instructions.
16. The method of claim 2 , wherein the method comprises once or twice daily topical application of therapeutically effective amounts of the said composition to the skin portion of the subject affected by said psoriasis until the skin is cured or alleviated or according to doctor's instructions.
17. The method of claim 4 , wherein the method comprises once or twice daily topical application of therapeutically effective amounts of the said composition to the skin portion of the subject affected by the psoriasis until the skin is cured or alleviated or according to doctor's instructions.
18. The method of claim 6 , wherein the method comprises once or twice daily topical application of therapeutically effective amounts of the said composition to the skin portion of the subject affected by said psoriasis until the skin is cured or alleviated or according to doctor's instructions.
19. The method of claim 2 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride, from about 0.01% w/w to about 1% w/w, from about 1% w/w to about 3% w/w, or from about 3% w/w to about 5% w/w tapinarof and from about 10% to about 98% w/w at least one penetration enhancer.
20. The method of claim 2 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride, from about 0.01% w/w to about 1% w/w, from about 1% w/w to about 3% w/w or from about 3% w/w to about 5% w/w tofacitinib citrate and from about 10% to about 98% w/w at least one penetration enhancer.
21. The method of claim 2 , wherein said composition is a topical composition comprising from about 3% w/w to about 5% w/w or from about 5% w/w to about 10% w/w erlotinib or erlotinib hydrochloride, from about 0.01% w/w to about 1% w/w or from about 1% w/w to about 3% w/w roflumilast and from about 10% w/w to about 98% w/w at least one penetration enhancer.